Endometrial cancer is the third most common malignancy in women. The endometrioid adenocarcinomas represent 75% to 80% of the pathological subtypes. Ninety per cent of the lesions are stages I or II at diagnosis. Treatment strategies are based on surgery and radiotherapy, but the respective place of external irradiation and intracavitary brachytherapy is not strictly established. The role of pelvic lymphadenectomy and the role of chemotherapy for aggressive histologies or locally advanced disease remain also controversial issues. The question <<which radiotherapy for which patient?>> is still debatable. Hence, although the answers we will provide may clarify some issues, they will not remove all uncertainties.